It’s journal club time! If you've been paying attention to the news this week, you probably saw that Pfizer is voluntarily withdrawing Oxbryta (voxelotor) from the market due to safety concerns. This is an inherent (and unfortunate) risk for drugs approved under the FDA's accelerated approval pathway. Even though the drug itself bit the dust, this journal club still holds up!

Read More